Introduction: The association between obesity and clinically significant prostate cancer (PCa) is still a matter of debate. In this study, we evaluated the effect of body mass index (BMI) on the prediction of pathological unfavorable disease (UD), positive surgical margins (PSMs), and biochemical recurrence (BCR) in patients with clinically localized (≤cT2c) International Society of Urological Pathology (ISUP) grade group 1 PCa at biopsy. Methods: 427 patients with ISUP grade group 1 PCa who have undergone radical prostatectomy and BMI evaluation were included. The outcome of interest was the presence of UD (defined as ISUP grade group ≥3 and pT ≥3a), PSM, and BCR. Results: Statistically significant differences resulted in comparing BMI with prostate-specific antigen (PSA) and serum testosterone levels (both p < 0.0001). Patients with UD and PSM had higher BMI values (p < 0.0001 and p = 0.006, respectively). BCR-free survival was significantly decreased in patients with higher BMI values (p < 0.0001). BMI was an independent risk factor for BCR and PSM. Receiver-operating characteristic analysis testing PSA accuracy in different BMI groups, showed that PSA had a reduced predictive value (area under the curve [AUC] = 0.535; 95% confidence interval [CI] = 0.422–0.646), in obese men compared to overweight (AUC = 0.664; 95% CI = 0.598–0.725) and normal weight patients (AUC = 0.721; 95% CI = 0.660–0.777). Conclusion: Our findings show that increased BMI is a significant predictor of UD and PSM at RP in patients with preoperative low-to intermediate-risk diseases, suggesting that BMI evaluation may be useful in a clinical setting to identify patients with favorable preoperative disease characteristics harboring high-risk PCa.

1.
World Health Organization
.
Obesity: preventing and managing the global epidemic: report of a WHO consultation on obesity, Geneva, 3–5 June 1997
.
Geneva, Switzerland
:
World Health Organization
;
1998
.
2.
Jensen
MD
.
Role of body fat distribution and the metabolic complications of obesity
.
J Clin Endocrinol Metab
.
2008
;
93
(
11 Suppl 1
):
S57
63
. .
3.
Despres
JP
,
Lemieux
I
.
Abdominal obesity and metabolic syndrome
.
Nature
.
2006
;
444
:
881
7
.
4.
Mathieu
P
,
Poirier
P
,
Pibarot
P
,
Lemieux
I
,
Després
JP
.
Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease
.
Hypertension
.
2009
;
53
:
577
84
. .
5.
Calle
EE
,
Kaaks
R
.
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
.
Nat Rev Cancer
.
2004
;
4
:
579
91
. .
6.
Ferro
M
,
Vartolomei
MD
,
Russo
GI
,
Cantiello
F
,
Farhan
ARA
,
Terracciano
D
,
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer
.
World J Urol
.
2019
;
37
(
3
):
507
14
. .
7.
Ferro
M
,
Katalin
MO
,
Buonerba
C
,
Marian
R
,
Cantiello
F
,
Musi
G
,
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor
.
Urol Oncol
.
2020
;
38
(
5
):
459
64
. .
8.
Ferro
M
,
Di Lorenzo
G
,
Buonerba
C
,
Lucarelli
G
,
Russo
GI
,
Cantiello
F
,
Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade 3 bladder cancer
.
J Cancer
.
2018
;
9
(
22
):
4250
4
. Published 2018 Oct 20. .
9.
Lucarelli
G
,
Loizzo
D
,
Franzin
R
,
Battaglia
S
,
Ferro
M
,
Cantiello
F
,
Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma
.
Expert Rev Mol Diagn
.
2019
;
19
(
5
):
397
407
. .
10.
Lucarelli
G
,
Rutigliano
M
,
Galleggiante
V
,
Giglio
A
,
Palazzo
S
,
Ferro
M
,
Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer
.
Expert Rev Mol Diagn
.
2015
;
15
(
9
):
1211
24
. .
11.
Ferro
M
,
Terracciano
D
,
Buonerba
C
,
Lucarelli
G
,
Bottero
D
,
Perdonà
S
,
The emerging role of obesity, diet and lipid metabolism in prostate cancer
.
Future Oncol
.
2017
;
13
(
3
):
285
93
. .
12.
Lucarelli
G
,
Loizzo
D
,
Ferro
M
,
Rutigliano
M
,
Vartolomei
MD
,
Cantiello
F
,
Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update
.
Expert Rev Mol Diagn
.
2019
;
19
(
5
):
377
87
. .
13.
Ferro
M
,
Lucarelli
G
,
Bruzzese
D
,
Di Lorenzo
G
,
Perdonà
S
,
Autorino
R
,
Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance
.
Oncotarget
.
2017
;
8
(
11
):
18424
34
. .
14.
Ferro
M
,
Lucarelli
G
,
de Cobelli
O
,
Vartolomei
MD
,
Damiano
R
,
Cantiello
F
,
Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies
.
World J Urol
.
2020
. Published online ahead of print 2020 Jul 18.
15.
Rundle
A
,
Wang
Y
,
Sadasivan
S
,
Chitale
DA
,
Gupta
NS
,
Tang
D
,
Larger men have larger prostates: detection bias in epidemiologic studies of obesity and prostate cancer risk
.
Prostate
.
2017
;
77
(
9
):
949
54
. .
16.
Freedland
SJ
,
Grubb
KA
,
Yiu
SK
,
Nielsen
ME
,
Mangold
LA
,
Isaacs
WB
,
Obesity and capsular incision at the time of open retropubic radical prostatectomy
.
J Urol
.
2005
;
174
(
5
):
1798
801
. .
17.
Epstein
JI
,
Egevad
L
,
Amin
MB
,
Delahunt
B
,
Srigley
JR
,
Humphrey
PA
.
The 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system
.
Am J Surg Pathol
.
2016
;
40
(
2
):
244
52
. .
18.
Epstein
JI
,
Amin
MB
,
Reuter
VE
,
Humphrey
PA
.
Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma
.
Am J Surg Pathol
.
2017
;
41
(
4
):
e1
7
. .
19.
Heidenreich
A
,
Bellmunt
J
,
Bolla
M
,
Joniau
S
,
Mason
M
,
Matveev
V
,
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
.
Eur Urol
.
2011
;
59
(
1
):
61
71
. .
20.
Calle
EE
,
Rodriguez
C
,
Walker-Thurmond
K
,
Thun
MJ
.
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults
.
N Engl J Med
.
2003
;
348
(
17
):
1625
38
. .
21.
Finley
DS
,
Calvert
VS
,
Inokuchi
J
,
Lau
A
,
Narula
N
,
Petricoin
EF
,
Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness
.
J Urol
.
2009
;
182
(
4
):
1621
7
. .
22.
von Hafe
P
,
Pina
F
,
Pérez
A
,
Tavares
M
,
Barros
H
.
Visceral fat accumulation as a risk factor for prostate cancer
.
Obes Res
.
2004 Dec
;
12
(
12
):
1930
5
. .
23.
Lucarelli
G
,
Ferro
M
,
Loizzo
D
,
Bianchi
C
,
Terracciano
D
,
Cantiello
F
,
Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma
.
Metabolites
.
2020
;
10
(
12
):
509
. Published 2020 Dec 13. .
24.
Netti
GS
,
Lucarelli
G
,
Spadaccino
F
,
Castellano
G
,
Gigante
M
,
Divella
C
,
PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma
.
Aging
.
2020
;
12
(
8
):
7585
602
. .
25.
Huang
J
,
Duran
A
,
Reina-Campos
M
,
Valencia
T
,
Castilla
EA
,
Müller
TD
,
Adipocyte p62/SQSTM1 suppresses tumorigenesis through opposite regulations of metabolism in adipose tissue and tumor
.
Cancer Cell
.
2018
;
33
(
4
):
770
84.e6
. .
26.
MacInnis
RJ
,
English
DR
.
Body size and composition and prostate cancer risk: systematic review and meta-regression analysis
.
Cancer Causes Control
.
2006
;
17
(
8
):
989
1003
. .
27.
Cao
Y
,
Ma
J
.
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis
.
Cancer Prev Res
.
2011
;
4
(
4
):
486
501
. .
28.
Rodriguez
C
,
Patel
AV
,
Calle
EE
,
Jacobs
EJ
,
Chao
A
,
Thun
MJ
.
Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States
.
Cancer Epidemiol Biomarkers Prev
.
2001
;
10
(
4
):
345
53
.
29.
Freedland
SJ
,
Sun
L
,
Kane
CJ
,
Presti
JC
,
Terris
MK
,
Amling
CL
,
Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases
.
BJU Int
.
2008
;
102
(
8
):
969
74
. .
30.
Bañez
LL
,
Hamilton
RJ
,
Partin
AW
,
Vollmer
RT
,
Sun
L
,
Rodriguez
C
,
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer
.
JAMA
.
2007
;
298
(
19
):
2275
80
. .
31.
Balakrishnan
AS
,
Cowan
JE
,
Cooperberg
MR
,
Shinohara
K
,
Nguyen
HG
,
Carroll
PR
.
Evaluating the safety of active surveillance: outcomes of deferred radical prostatectomy after an initial period of surveillance
.
J Urol
.
2019
;
202
(
3
):
506
10
. .
32.
Bhindi
B
,
Kulkarni
GS
,
Finelli
A
,
Alibhai
SM
,
Hamilton
RJ
,
Toi
A
,
Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly
.
Eur Urol
.
2014
;
66
(
5
):
841
8
. .
33.
de Cobelli
O
,
Terracciano
D
,
Tagliabue
E
,
Raimondi
S
,
Galasso
G
,
Cioffi
A
,
Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance
.
Urol Oncol
.
2015
;
33
(
5
):
201
8
. .
34.
Yu
YD
,
Byun
SS
,
Lee
SE
,
Hong
SK
.
Impact of body mass index on oncological outcomes of prostate cancer patients after radical prostatectomy
.
Sci Rep
.
2018
;
8
(
1
):
11962
. Published 2018 Aug 10. .
35.
Park
J
,
Euhus
DM
,
Scherer
PE
.
Paracrine and endocrine effects of adipose tissue on cancer development and progression
.
Endocr Rev
.
2011
;
32
(
4
):
550
70
. .
36.
Bassett
JK
,
Severi
G
,
Baglietto
L
,
MacInnis
RJ
,
Hoang
HN
,
Hopper
JL
,
Weight change and prostate cancer incidence and mortality
.
Int J Cancer
.
2012
;
131
(
7
):
1711
9
. .
37.
Bhindi
B
,
Trottier
G
,
Elharram
M
,
Fernandes
KA
,
Lockwood
G
,
Toi
A
,
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer
.
BJU Int
.
2012
;
110
(
7
):
980
6
. .
38.
van Roermund
JG
,
Hinnen
KA
,
Tolman
CJ
,
Bol
GH
,
Witjes
JA
,
Bosch
JL
,
Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients
.
BJU Int
.
2011
;
107
(
11
):
1775
9
. .
39.
Woo
S
,
Cho
JY
,
Kim
SY
,
Kim
SH
.
Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer
.
AJR Am J Roentgenol
.
2015
;
204
(
1
):
W43
7
. .
40.
Salji
M
,
Hendry
J
,
Patel
A
,
Ahmad
I
,
Nixon
C
,
Leung
HY
.
Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer
.
Eur Urol Focus
.
2018
;
4
(
6
):
858
66
. .
41.
Sasaki
T
,
Sugino
Y
,
Kato
M
,
Nishikawa
K
,
Kanda
H
.
Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-naïve men with advanced prostate cancer
.
Int J Clin Oncol
.
2020
;
25
(
2
):
370
6
. .
42.
StrulovShachar
S
,
Williams
GR
.
The obesity paradox in cancer-moving beyond BMI
.
Cancer Epidemiol Biomarkers Prev
.
2017
;
26
(
1
):
13
6
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.